|
XL092 Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: Zanzalintinib
Pipeline
Phase 1: 1Phase 2: 2
Top Sponsors
- University of Utah1
- UNC Lineberger Comprehensive Cancer Center1
- Karie Runcie1
Indications
- Cancer3
- Advanced Renal Cell Carcinoma1
- Clear Cell Renal Cell Carcinoma1
- Metastatic Renal Cell Carcinoma1
- Metastatic Castration-resistant Prostate Cancer1
Boston, Massachusetts1 trial
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Dana Farber/Harvard Cancer Center
Phase 1
St Louis, Missouri1 trial
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Washington University School of Medicine
Phase 2
Salt Lake City, Utah1 trial
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Huntsman Cancer Institute at University of Utah
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.